Get the Stockscreener App
4.25
4.57%
0.17
Aligos Therapeutics Inc stock is traded at $4.25, with a volume of 12,214.
It is up +4.57% in the last 24 hours and down -23.40% over the past month.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
See More
Previous Close:
$4.08
Open:
$4.09
24h Volume:
12,214
Relative Volume:
0.07
Market Cap:
$26.11M
Revenue:
$4.71M
Net Income/Loss:
$-90.32M
P/E Ratio:
-0.4883
EPS:
-8.7032
Net Cash Flow:
$-85.19M
1W Performance:
-19.20%
1M Performance:
-23.40%
6M Performance:
-50.33%
1Y Performance:
-53.27%
1-Day Range:
$4.01
$4.27
1-Week Range:
$4.00
$5.80
52-Week Range:
$4.00
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
4.2201 | 25.25M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
485.27 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
673.63 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
908.80 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.65 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.95 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Resumed | Jefferies | Buy |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics Inc (ALGS) Income Statement - TradingKey
Aligos Therapeutics Inc (ALGS) Balance Sheet - TradingKey
Aligos Therapeutics Inc (ALGS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aligos Therapeutics Inc (ALGS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
Avoiding Lag: Real-Time Signals in (ALGS) Movement - Stock Traders Daily
Aligos Therapeutics Inc (ALGS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALGS Q2'26 Earnings: revenue estimate is 24.68M USD - TradingView
Aligos Therapeutics (ALGS) Holds Steady Near Support Amid Cautious TradingBlock Trade Flow - dars.gov.et
H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Aligos stock rating on trial enrollment - Investing.com
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Aligos Completes Phase 2 B-SUPREME Enrollment - t.co
Aligos Therapeutics stock is trending overnight: Here's what's going on with ALGS stock - MSN
Aligos Therapeutics Shares Decline 5.44% as Stock Tests Key Support LevelSymmetrical Triangle - dars.gov.et
Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment - Moomoo
Aligos Therapeutics (ALGS) Completes Enrollment for Phase 2 Stud - GuruFocus
Aligos completes enrollment in phase 2 hepatitis B study By Investing.com - Investing.com Australia
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection - Investing News Network
Aligos completes enrollment in phase 2 hepatitis B study - Investing.com
Pevifoscorvir HBV trial fully enrolled; first key data expected in late 3Q 2027 - Stock Titan
ALGS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALGS stock rallies 16% after-hours on $25M cash boost from China hepatitis B drug deal - MSN
H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy - Investing.com
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
Aligos Therapeutics Secures $25M Upfront Payment in Licensing De - GuruFocus
Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock - Benzinga
Aligos receives $25M upfront payment from China licensing deal - Investing.com UK
Aligos receives $25M upfront payment from China licensing deal By Investing.com - Investing.com India
Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech - Moomoo
Aligos Therapeutics stock jumps on $25M China licensing deal By Investing.com - Investing.com Australia
Why is Aligos Therapeutics stock surging today? By Investing.com - Investing.com Canada
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Investing News Network
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):